Renée V Gardner1. 1. Department of Pediatrics, Louisiana State University Health Sciences Center, Children's Hospital of New Orleans, New Orleans, LA.
Abstract
BACKGROUND: Sickle cell disease causes significant morbidity and mortality and affects the economic and healthcare status of many countries. Yet historically, the disease has not had commensurate outlays of funds that have been aimed at research and development of drugs and treatment procedures for other diseases. METHODS: This review examines several treatment modalities and new drugs developed since the late 1990s that have been used to improve outcomes for patients with sickle cell disease. RESULTS: Targeted therapies based upon the pathophysiologic mechanisms of sickle cell disease that result in organ dysfunction and painful episodes include hydroxyurea, L-glutamine, crizanlizumab, and other drugs that are currently on the market or are on the verge of becoming available. These agents have the potential to improve survival and quality of life for individuals with sickle cell disease. Also discussed is stem cell transplantation that, to date, is the only curative approach for this disease, as well as the current status of gene therapy. CONCLUSION: These examples demonstrate how the current knowledge of sickle cell disease pathophysiology and treatment approaches intersect. Although interest in sickle cell research has blossomed, many more clinical trials need to be initiated and subjected to more strenuous examination and analysis than have been used in the past.
BACKGROUND: Sickle cell disease causes significant morbidity and mortality and affects the economic and healthcare status of many countries. Yet historically, the disease has not had commensurate outlays of funds that have been aimed at research and development of drugs and treatment procedures for other diseases. METHODS: This review examines several treatment modalities and new drugs developed since the late 1990s that have been used to improve outcomes for patients with sickle cell disease. RESULTS: Targeted therapies based upon the pathophysiologic mechanisms of sickle cell disease that result in organ dysfunction and painful episodes include hydroxyurea, L-glutamine, crizanlizumab, and other drugs that are currently on the market or are on the verge of becoming available. These agents have the potential to improve survival and quality of life for individuals with sickle cell disease. Also discussed is stem cell transplantation that, to date, is the only curative approach for this disease, as well as the current status of gene therapy. CONCLUSION: These examples demonstrate how the current knowledge of sickle cell disease pathophysiology and treatment approaches intersect. Although interest in sickle cell research has blossomed, many more clinical trials need to be initiated and subjected to more strenuous examination and analysis than have been used in the past.
Authors: Aslihan Turhan; Linnea A Weiss; Narla Mohandas; Barry S Coller; Paul S Frenette Journal: Proc Natl Acad Sci U S A Date: 2002-03-05 Impact factor: 11.205
Authors: E P Orringer; J F Casella; K I Ataga; M Koshy; P Adams-Graves; L Luchtman-Jones; T Wun; M Watanabe; F Shafer; A Kutlar; M Abboud; M Steinberg; B Adler; P Swerdlow; C Terregino; S Saccente; B Files; S Ballas; R Brown; S Wojtowicz-Praga; J M Grindel Journal: JAMA Date: 2001-11-07 Impact factor: 56.272
Authors: M C Walters; M Patience; W Leisenring; Z R Rogers; V M Aquino; G R Buchanan; I A Roberts; A M Yeager; L Hsu; T Adamkiewicz; J Kurtzberg; E Vichinsky; B Storer; R Storb; K M Sullivan Journal: Biol Blood Marrow Transplant Date: 2001 Impact factor: 5.742
Authors: Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin Journal: Nat Med Date: 2002-11-11 Impact factor: 53.440
Authors: Charles Antwi-Boasiako; Michael M Asare; Ibrahim Baba; Alfred Doku; Kevin Adutwum-Ofosu; Charles Hayfron-Benjamin; Chamila P Asare; Robert Aryee; Gifty Boatemaah Dankwah; John Ahenkorah Journal: Am J Blood Res Date: 2021-04-15